WAM
OTLK icon

Warberg Asset Management’s Outlook Therapeutics OTLK Stock Holding History

Warberg Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-275,000
Closed -$56.4K – 195
2026
Q1 		$56.4K Buy
+275,000
New +$119K 0.01% 146

Other funds holding OTLK

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM

Warberg Asset Management's OTLK Position: Q2 2026 in Review

Warberg Asset Management sold out of Outlook Therapeutics (OTLK) in Q2 2026, closing a stake of 275,000 shares — an estimated $56.4K sold.

Warberg Asset Management first reported a position in OTLK in Q1 2026 and held it in 1 quarter. The position peaked at $56.4K in Q1 2026. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Warberg Asset Management reported no remaining Outlook Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Warberg Asset Management sold 275,000 Outlook Therapeutics shares in Q2 2026, an estimated $56.4K.
  • Warberg Asset Management first reported a position in Outlook Therapeutics in Q1 2026 and held it in 1 quarter.
  • Warberg Asset Management's Outlook Therapeutics position peaked at $56.4K in Q1 2026.
  • 69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Warberg Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.